Verition Fund Management
MIRM icon

Verition Fund Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Verition Fund Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,251
Closed -$652K – 3070
2025
Q4 		$652K Buy
+8,251
New +$592K ﹤0.01% 2470
2025
Q3 		– Sell
-22,551
Closed -$1.15M – 3912
2025
Q2 		$1.15M Buy
22,551
+14,093
+167% +$627K 0.01% 2364
2025
Q1 		$381K Sell
8,458
-36,412
-81% -$1.72M ﹤0.01% 2737
2024
Q4 		$1.86M Buy
44,870
+31,855
+245% +$1.33M 0.01% 1601
2024
Q3 		$508K Buy
+13,015
New +$519K ﹤0.01% 2314
2023
Q4 		– Sell
-19,400
Closed -$613K – 2557
2023
Q3 		$613K Buy
+19,400
New +$531K 0.01% 1315
2021
Q1 		– Sell
-97,066
Closed -$1.7M – 1681
2020
Q4 		$1.7M Buy
+97,066
New +$1.91M 0.01% 407

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Verition Fund Management's MIRM Position: Q1 2026 in Review

Verition Fund Management sold out of Mirum Pharmaceuticals (MIRM) in Q1 2026, closing a stake of 8,251 shares — an estimated $652K sold.

Verition Fund Management first reported a position in MIRM in Q4 2020 and held it in 7 quarters. The position peaked at $1.86M in Q4 2024. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Verition Fund Management reported no remaining Mirum Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 8,251 Mirum Pharmaceuticals shares in Q1 2026, an estimated $652K.
  • Verition Fund Management first reported a position in Mirum Pharmaceuticals in Q4 2020 and held it in 7 quarters.
  • Verition Fund Management's Mirum Pharmaceuticals position peaked at $1.86M in Q4 2024.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.